Literature DB >> 23145864

Efficacy of probing with mitomycin-C in adults with primary acquired nasolacrimal duct obstruction.

Manish Kumar Sinha1, Mandeep S Bajaj, Neelam Pushker, Supriyo Ghose, Mahesh Chandra.   

Abstract

PURPOSE: To evaluate the efficacy and safety of adjunctive mitomycin-c (MMC) during probing in adults with primary nasolacrimal duct (NLD) obstruction.
METHODS: This is a prospective, comparative, randomized interventional study. A total of 40 adult patients with unilateral epiphora caused by primary NLD obstruction were treated and evaluated. Lacrimal probing and irrigation with adjunctive MMC (1 mL of 0.2 mg/mL, once) in cases and only probing in controls were done. At the end of 3 months, subjective improvement in epiphora and patency on syringing were evaluated.
RESULTS: Complete subjective improvement in epiphora was found in 15% of cases as opposed to 0% in controls, at 3 months of follow-up. Moderate improvement was seen in 25% of cases as opposed to 5% of controls. Mild improvement was seen in 25% of cases as opposed to 35% in controls. The overall subjective improvement was seen in 65% of cases as opposed to 40% in controls. On syringing, NLD was patent in 30% of cases as opposed to 10% in controls at 3 months of follow-up, which was not significant.
CONCLUSIONS: Use of intraoperative MMC improves the success of probing to some extent. Being a minimally invasive procedure, it can be tried in patients who refuse or are not systemically fit for undergoing dacryocystorhinostomy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23145864     DOI: 10.1089/jop.2012.0083

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  4 in total

1.  Probing with mitomycin-C in adults with nasolacrimal duct obstruction.

Authors:  Mohamed Amin Ghobadifar; Nader Degani; Iman Dezhkam; Nazanin Rezaei
Journal:  J Ocul Pharmacol Ther       Date:  2013-03-26       Impact factor: 2.671

2.  Evaluation of lacrimal duct probing in adults with 0.02% and 0.04% mitomycin-C in primary acquired nasolacrimal duct obstruction: A randomized comparative pilot study.

Authors:  Manu Saini; Mandeep Singh Bajaj; Neelam Pushker; Rachna Meel; Kulbhushan Saini; Shweta Chaurasia; Aditi Mehta
Journal:  Oman J Ophthalmol       Date:  2022-03-02

3.  Nine-Month Follow-up Results of Treatment for Nasolacrimal Duct Obstruction by Probing with Adjunctive Mitomycin C in Adults: A Prospective Randomized Placebo-Controlled Trial.

Authors:  Nader Dehghani; Mohamad Reza Fouladivanda; Mohamed Amin Ghobadifar; Gelayol Safshekan-Esfahani; Armin Akbarzadeh
Journal:  Chonnam Med J       Date:  2015-04-14

4.  Intra-Operative Mitomycin-C as Adjuvant Therapy in External and Endonasal Dacryocystorhinostomy: Systematic Review and Meta-Analysis.

Authors:  Tamata T S Sousa; Silvana A Schellini; Roberta L F S Meneghim; Antonio J M Cataneo
Journal:  Ophthalmol Ther       Date:  2020-04-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.